Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MYGN Myriad Genetics	$5.03 -3.1%	$5.86	$3.81 ▼ $29.30	$463.65M	1.84	1.23 million shs	1.30 million shs
RGLS Regulus Therapeutics	$8.11 +0.4%	$6.00	$0.83 ▼ $8.35	$561.49M	0.35	941,067 shs	970,988 shs
SPPI Spectrum Pharmaceuticals	$1.03	$1.01	$0.32 ▼ $1.57	$211.41M	2.15	1.93 million shs	N/A
ZBIO Zenas Biopharma	$10.33 -8.7%	$9.90	$5.83 ▼ $26.25	$432.15M	N/A	188,488 shs	171,960 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MYGN Myriad Genetics	0.00%	-1.18%	+21.79%	-50.30%	-78.32%
RGLS Regulus Therapeutics	0.00%	-1.34%	+3.05%	+491.97%	+236.51%
SPPI Spectrum Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
ZBIO Zenas Biopharma	0.00%	-7.10%	-1.34%	+1,032,999,900.00%	+1,032,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MYGN Myriad Genetics	4.1898 of 5 stars	4.1	1.0	0.0	4.1	3.0	1.7	0.6
RGLS Regulus Therapeutics	1.5856 of 5 stars	2.1	3.0	0.0	0.0	2.4	3.3	0.0
SPPI Spectrum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZBIO Zenas Biopharma	1.2751 of 5 stars	3.5	0.0	0.0	0.0	1.1	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MYGN Myriad Genetics	2.13	Hold	$14.38	185.98% Upside
RGLS Regulus Therapeutics	2.29	Hold	$8.50	4.81% Upside
SPPI Spectrum Pharmaceuticals	0.00	N/A	N/A	N/A
ZBIO Zenas Biopharma	3.00	Buy	$36.67	254.95% Upside

Current Analyst Ratings Breakdown

Latest SPPI, RGLS, ZBIO, and MYGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	MYGN Myriad Genetics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$20.00 ➝ $6.00
5/16/2025	ZBIO Zenas Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/15/2025	MYGN Myriad Genetics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$12.50 ➝ $9.00
5/15/2025	ZBIO Zenas Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$35.00
5/8/2025	MYGN Myriad Genetics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Peer Perform
5/7/2025	MYGN Myriad Genetics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$18.00
5/7/2025	MYGN Myriad Genetics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $8.00
5/7/2025	MYGN Myriad Genetics	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$19.00 ➝ $10.00
5/7/2025	MYGN Myriad Genetics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $7.00
5/7/2025	MYGN Myriad Genetics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$22.00 ➝ $6.00
5/1/2025	RGLS Regulus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$9.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MYGN Myriad Genetics	$831.30M	0.56	N/A	N/A	$9.53 per share	0.53
RGLS Regulus Therapeutics	N/A	N/A	N/A	N/A	$1.05 per share	N/A
SPPI Spectrum Pharmaceuticals	$10.11M	20.91	N/A	N/A	$0.15 per share	6.87
ZBIO Zenas Biopharma	$15M	28.81	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MYGN Myriad Genetics	-$263.30M	-$1.12	N/A	N/A	N/A	-14.09%	-4.51%	-3.07%	8/5/2025 (Estimated)
RGLS Regulus Therapeutics	-$30.04M	-$0.73	N/A	N/A	N/A	N/A	-53.07%	-48.58%	8/6/2025 (Estimated)
SPPI Spectrum Pharmaceuticals	-$75.40M	-$0.36	N/A	14.71	N/A	N/A	-218.44%	-66.16%	N/A
ZBIO Zenas Biopharma	N/A	-$3.55	N/A	∞	N/A	N/A	N/A	N/A	8/21/2025 (Estimated)

Latest SPPI, RGLS, ZBIO, and MYGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	ZBIO Zenas Biopharma	-$1.15	-$0.80	+$0.35	-$0.80	$5.00 million	$10.00 million
5/8/2025	Q1 2025	RGLS Regulus Therapeutics	-$0.29	-$0.15	+$0.14	-$0.15	N/A	N/A
5/6/2025	Q1 2025	MYGN Myriad Genetics	-$0.05	-$0.03	+$0.02	N/A	$200.37 million	$195.90 million
3/20/2025	Q4 2024	RGLS Regulus Therapeutics	-$0.20	-$0.20	N/A	-$0.20	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MYGN Myriad Genetics	N/A	N/A	N/A	N/A	N/A
RGLS Regulus Therapeutics	N/A	N/A	N/A	N/A	N/A
SPPI Spectrum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZBIO Zenas Biopharma	$0.05	0.46%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MYGN Myriad Genetics	0.05	1.90	1.73
RGLS Regulus Therapeutics	N/A	14.15	14.14
SPPI Spectrum Pharmaceuticals	N/A	2.71	2.38
ZBIO Zenas Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MYGN Myriad Genetics	99.02%
RGLS Regulus Therapeutics	92.38%
SPPI Spectrum Pharmaceuticals	21.67%
ZBIO Zenas Biopharma	N/A

Insider Ownership

Company	Insider Ownership
MYGN Myriad Genetics	2.40%
RGLS Regulus Therapeutics	4.35%
SPPI Spectrum Pharmaceuticals	2.70%
ZBIO Zenas Biopharma	16.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MYGN Myriad Genetics	2,600	92.18 million	89.12 million	Optionable
RGLS Regulus Therapeutics	30	69.23 million	62.65 million	Optionable
SPPI Spectrum Pharmaceuticals	86	205.25 million	199.70 million	Optionable
ZBIO Zenas Biopharma	N/A	41.83 million	N/A	N/A

SPPI, RGLS, ZBIO, and MYGN Headlines

Recent News About These Companies

June 16, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ZBIO

June 16 at 5:45 AM | prnewswire.com

ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors - Lead Plaintiff Deadline June 16, 2025

June 16 at 4:20 AM | accessnewswire.com

FINAL ALERT NOTICE - ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO

June 16 at 3:44 AM | prnewswire.com

Securities Fraud Class Action Filed Against Zenas BioPharma, Inc. (ZBIO) - Levi & Korsinsky Reminds Investors of June 16, 2025

June 15 at 7:27 PM | accessnewswire.com

ZBIO IMPORTANT DEADLINE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Zenas BioPharma, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important June 16 Deadline in Securities Class Action First Filed by The Firm - ZBIO

June 15 at 6:18 PM | accessnewswire.com

Zenas BioPharma, Inc. (ZBIO) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before June 16, 2025

June 15 at 1:05 PM | accessnewswire.com

Zenas BioPharma, Inc. (ZBIO) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of June 16, 2025 Deadline

June 15 at 11:00 AM | accessnewswire.com

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

June 15 at 10:44 AM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO

June 15 at 10:00 AM | globenewswire.com

Recover Investment Losses: Levi & Korsinsky Files Class Action Against Zenas BioPharma, Inc. (ZBIO)

June 15 at 8:05 AM | accessnewswire.com

FINAL ZBIO DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Zenas BioPharma, Inc. Investors to Join the Class Action Lawsuit

June 15 at 7:00 AM | accessnewswire.com

Join Class Action to Recover Losses from Zenas BioPharma, Inc. (ZBIO) - Contact Levi & Korsinsky Before June 16, 2025

June 14 at 10:39 PM | accessnewswire.com

Investor Alert: Deadline Approaching to Join Zenas BioPharma, Inc. (ZBIO) Class Action - Contact Levi & Korsinsky

June 14 at 9:37 PM | accessnewswire.com

ZBIO DEADLINE ALERT: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Zenas BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 16 Deadline in Securities Class Action First Filed by the Firm - ZBIO

June 14 at 7:28 PM | accessnewswire.com

ZBIO ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against Zenas BioPharma, Inc. - June 16, 2025 Deadline

June 14 at 6:30 PM | accessnewswire.com

ZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors - Lead Plaintiff Deadline June 16, 2025

June 13 at 5:10 PM | accessnewswire.com

ZBIO Deadline: ZBIO Investors with Losses in Excess of $100K Have Opportunity to Lead Zenas BioPharma, Inc. Securities Lawsuit Filed by The Rosen Law Firm

June 13 at 4:45 PM | prnewswire.com

ZBIO ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against Zenas BioPharma, Inc. - June 16, 2025 Deadline

June 13 at 1:45 PM | accessnewswire.com

Zenas BioPharma, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights – ZBIO

June 13 at 1:23 PM | globenewswire.com

ZBIO IMPORTANT DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Zenas BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 16 Deadline in Securities Class Action First Filed by the Firm – ZBIO

June 13 at 1:11 PM | globenewswire.com

Zenas Biopharma Inc (NASDAQ:ZBIO) Shares Sold by Wellington Management Group LLP

June 3, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPPI, RGLS, ZBIO, and MYGN Company Descriptions

Myriad Genetics NASDAQ:MYGN

$5.03 -0.16 (-3.08%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$4.99 -0.04 (-0.80%)

As of 05:11 AM Eastern

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Regulus Therapeutics NASDAQ:RGLS

$8.11 +0.03 (+0.37%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$8.09 -0.02 (-0.26%)

As of 05:36 AM Eastern

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Spectrum Pharmaceuticals NASDAQ:SPPI

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.

Zenas Biopharma NASDAQ:ZBIO

$10.33 -0.99 (-8.75%)

As of 06/13/2025 04:00 PM Eastern

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time